glp-1 receptor agonist type 1 diabetes randomized trial agonists in the treatment of 2 – state-of-the-art Pharmacogenetics of Glucagon-like-peptide-1 receptor in

(GLP-1) Agonists Restraining factors Regulatory Standards : Restricted FDA and other regulatory standards for new medication approval can hamper the growth of the GLP-1 Agonists market

And both conspire regarding metabolic adaptation to start bringing you back up

[DOI] [PMC free article] [PubMed] [Google Scholar] 17

Gestational diabetes mellitus

Endogenous hyperinsulinemia may cause weight gain and obesity [30], and treatment with insulin causes substantial weight gain, and may even increase cardiovascular risk [31]

And what then, refers to or indicates strictly muscle tissue,.say if we were reading a DEXA scan or something